Wuhan Hiteck Biological Pharma Co Ltd Net Asset Quality Index
Wuhan Hiteck Biological Pharma Co Ltd net asset quality index. Wuhan Hiteck Biological Pharma Co Ltd (300683) has a Net Asset Quality Index of 84.6% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.47 Billion minus total liabilities of CN¥381.30 Million yields net assets of CN¥2.09 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check how high is Wuhan Hiteck Biological Pharma Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Wuhan Hiteck Biological Pharma Co Ltd (2013–2025)
Net asset quality index of Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2025. This chart shows how Wuhan Hiteck Biological Pharma Co Ltd's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of June 2026, the index stands at 84.6%, representing net assets of CN¥2.09 Billion against total assets of CN¥2.47 Billion CNY. See Wuhan Hiteck Biological Pharma Co Ltd book value and equity for net asset value and shareholders' equity analysis.
Wuhan Hiteck Biological Pharma Co Ltd Net Asset Quality Index by Year (2013–2025)
Wuhan Hiteck Biological Pharma Co Ltd net asset quality index by year from 2013 to 2025. The table below presents the year-by-year Net Asset Quality Index for Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Wuhan Hiteck Biological Pharma Co Ltd stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 84.2% | CN¥2.17 Billion | CN¥2.58 Billion | CN¥407.14 Million | ▲ +2.1 pp |
| 2024 | 82.1% | CN¥2.41 Billion | CN¥2.94 Billion | CN¥525.05 Million | ▼ -1.9 pp |
| 2023 | 84.0% | CN¥2.50 Billion | CN¥2.97 Billion | CN¥475.73 Million | ▼ -2.3 pp |
| 2022 | 86.3% | CN¥2.34 Billion | CN¥2.71 Billion | CN¥371.20 Million | ▼ -0.6 pp |
| 2021 | 86.9% | CN¥2.34 Billion | CN¥2.70 Billion | CN¥354.46 Million | ▲ +8.0 pp |
| 2020 | 78.9% | CN¥1.72 Billion | CN¥2.19 Billion | CN¥461.62 Million | ▼ -2.3 pp |
| 2019 | 81.1% | CN¥1.76 Billion | CN¥2.17 Billion | CN¥409.03 Million | ▲ +1.8 pp |
| 2018 | 79.3% | CN¥1.71 Billion | CN¥2.16 Billion | CN¥445.77 Million | ▼ -6.8 pp |
| 2017 | 86.1% | CN¥1.64 Billion | CN¥1.91 Billion | CN¥265.62 Million | ▲ +18.4 pp |
| 2016 | 67.7% | CN¥703.35 Million | CN¥1.04 Billion | CN¥335.87 Million | ▼ -0.7 pp |
| 2015 | 68.4% | CN¥596.76 Million | CN¥872.49 Million | CN¥275.74 Million | ▲ +1.4 pp |
| 2014 | 67.0% | CN¥536.59 Million | CN¥801.37 Million | CN¥264.78 Million | ▲ +9.2 pp |
| 2013 | 57.7% | CN¥254.64 Million | CN¥441.07 Million | CN¥186.42 Million | — |